Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential for new option to improve convenience for patients -

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the presentation of positive data for VELCADE, the market-leading therapy for patients with multiple myeloma (MM) who have received at least one prior therapy. These data include results from a Phase II trial for subcutaneous (SC) administration of VELCADE, a new option under evaluation. Results were also presented from the international Phase III trial of VELCADE + DOXIL, which served as the basis for the recent U.S. approval of the combination and showed significant improvement in time to disease progression compared to VELCADE alone, the current standard of care. The VELCADE + DOXIL abstract was selected by the Best of the American Society of Clinical Oncology (ASCO) Program Committee as one of the premier abstracts at the 43rd Annual Meeting in Chicago.

"We and our partner Johnson & Johnson Pharmaceutical Research and Development L.L.C. continue to develop new clinical data that reinforce the role of VELCADE as the U.S. market-leading therapy in previously treated multiple myeloma," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "These data demonstrate that VELCADE in combination with another active agent can further strengthen the unparalleled impact of VELCADE. We are aggressively pursuing development of a subcutaneous delivery form to broaden alternatives for patients who prefer to receive VELCADE treatment at home."

Prospective Comparison of Subcutaneous to Intravenous Administration of Bortezomib in Patients with Multiple Myeloma: Pharmacokinetics, Efficacy and Toxicity (Abstract #8046)

This randomized trial evaluated the pharmacokinetics/pharmacodynamics (PK/PD), toxicity and response rate of VELCADE in patients treated with either an SC or intravenous
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
Post Your Comments:
(Date:9/30/2014)... Sept. 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... in the research, development and commercialization of prescription ophthalmic ... million advance from Hercules Technology Growth Capital, Inc. (NYSE: ... second and final advance under the Loan and Security ... Kingdom , Alimera Sciences Limited, entered into with ...
(Date:9/30/2014)... 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... the company,s Bridgewater, New Jersey ... and Drug Administration (FDA) relating to an inspection in ... Sculptra Aesthetic injectable, which was divested to Galderma S.A. ... of Valeant,s contract manufacturers (rather than Valeant,s own internal ...
(Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... launches integrated, multi-channel offerings for three fast-growing export sectors -- HONG KONG, Oct. 26 /PRNewswire-Asia/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
... Oct. 25 Stereotaxis, Inc. (Nasdaq: STXS ) announced ... quarter ended September 30, 2010, on Monday, November 1, ... will host a conference call and webcast on Monday, ... discuss the Company,s third quarter results and corporate developments. ...
Cached Medicine Technology:Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 2Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 3Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 4Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 5Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 6Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 7Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 8Global Sources launches integrated, multi-channel offerings for three fast-growing export sectors 9Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 2Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call 3
(Date:9/30/2014)... 2014 A new study of ... the impact of stress on metabolism after eating a high-fat ... from a fast food restaurant, about 930 calories and 60 ... 20 minutes every hour for 7 hours, conducting the study ... who had experienced a stressful event in their lives during ...
(Date:9/30/2014)... of allergy-related sudden deaths in the U.S., according to ... conducted by researchers at Montefiore Medical Center ... Yeshiva University . The study, published online today in ... also found that the risk of fatal drug-induced allergic ... and that such deaths increased significantly in the U.S. ...
(Date:9/30/2014)... 2014 Elevate , the latest product ... in and out of the gym by providing natural ingredients ... attention of Shane Michaels, prompting an investigative review. , ... reason most people simply just don’t have the ability to ... at work, getting the motivation to finish a project, or ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 With ... viral strains emerging every day, it’s a perfect ... The EnviroShield system is an electro-static disinfectant ... applications to surface normally missed with spray-on disinfectant ... nozzle that adds an electrostatic negative charge to ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Bifidobacteria, the ... with age, poor diet, and stress, so a high ... Each capsule of Ultimate Flora™ Men’s Complete ... cultures from 7 Bifidobacteria strains to support a healthy ... to build up, and 32 billion cultures from 7 ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
... WASHINGTON, Feb. 5 Following is a statement,by Daniel ... his last budget, the president had an opportunity to ... nation,s No. 1 killer,and costliest disease. Instead, his proposal ... cure. We,re making steady progress in combating heart,disease and ...
... precisely which bugs in the gut are involved in which ... bugs living in seven members of the same Chinese family. ... and trillions live symbiotically inside the human body. Different people ... them. , The makeup of each persons gut microflora ...
... West Pharmaceutical,Services, Inc. (NYSE: WST ) today ... Executive Officer, and William Federici, Chief,Financial Officer, will be ... 3:00 p.m. on February 11, 2008 in New York ... will be posted on the,investor link of the Company,s ...
... Compliance Corp. (OTC,Bulletin Board: SCOM) ("Sharps" or the ... small quantity generators of medical,waste, today announced that ... Officer, will present at the RedChip Small-Cap Investor,Conference ... approximately,10:10 a.m. MST (12:10 p.m. EST) on Thursday, ...
... LAKE FOREST, Ill., Feb. 5 BIOSAFE Laboratories, ... and Glycemion, the,United States distributor, have announced the ... use in schools to help identify diabetic and,pre-diabetic ... a two-part process comprised of an immediate fasting ...
... Rapid Growth, WAYNE, Pa., Feb. 5 ... communications,platform specifically designed for the biomedical research community,announced ... of myBW (or myBioWizard), a,unique personalization tool available ... now provides biomedical researchers access to approximately,half a ...
Cached Medicine News:Health News:Statement by Daniel W. Jones, M.D., American Heart Association President on President Bush's FY 2009 Budget Proposal 2Health News:Bug guts map brings scientists closer to understanding different bugs' role in the body 2Health News:Bug guts map brings scientists closer to understanding different bugs' role in the body 3Health News:West Pharmaceutical Services to Present at the 2008 UBS Global Healthcare Services Conference 2Health News:Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona 2Health News:BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessment Kits to U.S. School Children 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 2Health News:BioWizard Offers Conference Abstracts with the Launch of myBW 3
... Two Large Working Channels; 33 cm Working ... is the smallest ureteroscope with two large ... The ACMI MICRO-6 Ureteroscope reduces patient trauma ... or no dilation or general anesthesia. It ...
Smooth, contoured visual obturator provides less traumatic insertion through the urethra and into the bladder....
Semi-Rigid Ureteroscope...
... features a tip diameter of only ... up/down angulation range of 180 for ... areas.,For improved observation, a new optical ... reusable 11.7Fr (3.9mm) sheath dilator, 0.035" ...
Medicine Products: